ep6

EP6 is an inhibitor of 5-lipoxygenase (5-LO), which is a crucial enzyme of the arachidonic acid (AA) cascade and catalyzes the formation of bioactive leukotrienes (LTs) which are involved in inflammatory diseases and allergic reactions.

EP652 (compound 56) effectively inhibits the enzymatic activity of METTL3, with IC50 values of 2 nM in SPA, less than 10 nM in cellular assays, and 37 nM in ATPlite assays. It plays a significant role in both non-solid and solid tumor research.

Pep63, a neuroprotective peptide (VFQVRARTVA), enhances synaptic plasticity and memory. It competitively binds with Aβ1-42 oligomers, thereby inhibiting the formation of Aβ fibrils. Pep63 is employed in research focused on Alzheimer's disease (AD).

IP3RPEP6 serves as a competitive inhibitor of IP3R. Its IC50 values for IP3R1, IP3R2, and IP3R3 are 9.0 μM, 3.9 μM, and 4.3 μM, respectively. This compound does not affect ryanodine receptors and Cx43 hemichannels, and it is capable of modulating intracellular calcium signaling.

Alkyne-P60 is an effective 15-peptide inhibitor of Foxp3. It binds with Foxp3, inhibiting its nuclear translocation and attenuating the suppression of NFKB and NFAT functions mediated by Foxp3. Furthermore, Alkyne-P60 serves as a ligand for PROTAC target proteins.

CEP-6800 is a potent PARP inhibitor with potential anticancer activity. CEP-6800 could be used as a chemopotentiating agent with a variety of clinically effective chemotherapeutic agents.

γ-AA peptide P6 acts as a potent activator of E6 associated protein (E6AP), facilitating both its self-ubiquitination and the ubiquitination of E6AP substrates in vitro reconstituted reactions. Furthermore, γ-AA peptide P6 amplifies substrate ubiquitination within the cell, thereby expediting their proteasomal degradation [1].

PTBP1-RNA-binding inhibitor P6 TFA (PTBP1 α3-helix derived peptide P6 TFA) is a specific stapled peptide inhibitor of the splicing factor PTBP1, which is used to inhibit RNA alternative splicing events regulated by PTBP1. PTBP1-RNA-binding inhibitor P6 TFA exerts its effects by binding to the RNA recognition motif of PTBP1.

[Tyr6,D-Phe7,D-His9]-Substance P (6-11) is a tachykinin NK1 receptor antagonist that can counteract histamine-induced hyperalgesia.

Peptide P60 acts as a FOXP3 inhibitor. This compound can penetrate cells to hinder FOXP3's nuclear translocation and diminish its ability to suppress transcription factors NF-κB and NFAT. Peptide P60 also suppresses the immunosuppressive activity of regulatory T cells (Treg) derived from mice and humans, while enhancing effector T cell stimulation in vitro. Moreover, Peptide P60 can induce a lymphoproliferative autoimmune syndrome, displaying pathological characteristics similar to those observed in scurfy mice lacking functional Foxp3. Additionally, Peptide P60 has the potential to boost the immunogenicity of cancer and viral vaccines.